Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000288079 represents a **putative long noncoding RNA (antisense to the BOC locus)**. Antisense transcripts are RNA molecules transcribed from the DNA strand opposite to a protein-coding gene (in this case, BOC), often overlapping with parts of the sense gene[2][3][5]. Such RNAs can regulate gene expression at transcriptional, post-transcriptional, or epigenetic levels via mechanisms that include transcriptional interference, chromatin remodeling, RNA masking, miRNA regulation, and generation of endogenous siRNAs[2][3][1]. However, **the specific function and biological relevance of "novel transcript, antisense to BOC" remain uncharacterized**, and there are no known therapeutic interventions or disease associations directly linked to this transcript. Antisense lncRNAs are widely found in the genome, but only a few have established biological roles or therapeutic relevance[2][4]. Thus, **"novel transcript, antisense to BOC" is not a standard therapeutic target, and its presence in datasets primarily represents a genomic annotation rather than a confirmed molecular entity with known function or relevance in disease or drug action**[2][3][4][5]. - According to current research, antisense transcription can influence the expression of the protein-coding counterpart and modulate chromatin structure, but direct evidence for function at this specific locus is lacking[1][2][3]. - This entry is likely only a predicted, computationally annotated transcript without experimental validation or established relevance, so it does **not meet criteria for a canonical therapeutic target**. In summary: ENSG00000288079, or "novel transcript, antisense to BOC," is a provisionally annotated antisense long noncoding RNA gene without known function, molecular activity, or druggability, and is not a standard drug target. Its main distinguishing feature is its antisense orientation to the BOC gene; otherwise, it is not a canonical biological entity for therapeutic targeting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to BOC.